

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
December 1, 2015

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Kalyani Bhatt, BS, MS

Division of Advisory Committee and Consultant Management
Office of Executive Programs
Center for Drug Evaluation and Research

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

David Pickar, MD

Adjunct Professor of Psychiatry
Johns Hopkins Medical School and
Uniformed Services University of Health Sciences
Gabriel Sciences, LLC
Chevy Chase, Maryland

Murray B. Stein MD, MPH

Distinguished Professor of Psychiatry, Family
Medicine & Public Health
University of California San Diego
La Jolla, California

TEMPORARY MEMBERS (VOTING)

Ralph B. D'Agostino, Sr., PhD

(Acting Chairperson)
Professor of Mathematics/Statistics
Biostatistics and Epidemiology
Mathematics and Statistics Department
Executive Director MA/PhD Program in
Biostatistics
Director, Statistics and Consulting Unit
Boston University
Boston, Massachusetts

Victor De Gruttola, ScD *(via phone)*

Professor of Biostatistics
Department of Biostatistics
Harvard School of Public Health
Boston, Massachusetts

Dean Follmann, PhD

Assistant Director for Biostatistics
National Institute of Allergy and Infectious
Diseases
National Institutes of Health (NIH)
Bethesda, Maryland

Nitin Gogtay, MD

Director, Office of Clinical Research
National Institute of Mental Health, NIH
Bethesda, Maryland

Judith D. Goldberg, ScD

Professor of Biostatistics
Departments of Population Health and
Environmental Medicine
New York University School of Medicine
New York, New York

Jennifer Higgins, PhD

(Acting Consumer Representative)
Director, Strategic Planning and Business Development
Center for Human Development
Springfield, Massachusetts

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)

December 1, 2015

MEETING ROSTER (cont.)

Dawn F. Ionescu, MD

Depression Clinical and Research Program
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

J. John Mann, MD

Paul Janssen Professor of Translational Neuroscience
Director, Molecular Imaging and Neuropathology Division
Department of Psychiatry
Columbia University/New York State Psychiatric Institute
New York, New York

Rajesh Narendran, MD

Associate Professor in Radiology and Psychiatry
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Natalie Compagni Portis, PsyD

(Patient Representative)
Oakland, California

Matthew V. Rudorfer, MD

Associate Director for Treatment Research
Division of Services and Intervention Research
National Institute of Mental Health, NIH
Bethesda, Maryland

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Robert Russell Conley, MD

Global Development Leader, Pain and Core Therapeutics and Distinguished Scholar
Eli Lilly and Company
Indianapolis, Indiana

FDA PARTICIPANTS (Non-Voting)

John Jenkins, MD

Director
Office of New Drugs (OND)
CDER, FDA

Robert Temple, MD,

Deputy Director for Clinical Science
CDER, FDA
Deputy Director (Acting)
Office of Drug Evaluation-I (ODE-I)
OND, CDER, FDA

Mitchell Mathis, MD

Director
Division of Psychiatry Products
ODE-I, OND, CDER, FDA

Lisa LaVange, PhD

Director
Office of Biostatistics (OB)
Office of Translational Sciences (OTS)
CDER, FDA

Peiling Yang, PhD

Biostatistics Team Leader
Division of Biometrics I
OB, OTS, CDER, FDA